T. Rowe Price Associates’s Neurogene NGNE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q1 | – | Sell |
|
|||||
|
2024
Q4 | $2.82M | Buy |
|
|||||
|
2022
Q4 | – | Sell |
|
|||||
|
2022
Q3 | $13K | Hold |
|
|||||
|
2022
Q2 | $21K | Sell |
|
|||||
|
2022
Q1 | $44K | Buy |
|
|||||
|
2021
Q4 | $77K | Sell |
|
|||||
|
2021
Q3 | $117K | Sell |
|
|||||
|
2021
Q2 | $328K | Buy |
|
|||||
|
2021
Q1 | $377K | Buy |
|
|||||
|
2020
Q4 | $283K | Buy |
|
|||||
|
2020
Q3 | $160K | Buy |
|
|||||
|
2019
Q4 | – | Sell |
|
|||||
|
2019
Q3 | $1.15M | Buy |
|
|||||
|
2018
Q3 | – | Sell |
|
|||||
|
2018
Q2 | $3.58M | Sell |
|
|||||
|
2018
Q1 | $52.6M | Buy |
|
|||||
|
2017
Q4 | $39.7M | Sell |
|
|||||
|
2017
Q3 | $47.9M | Sell |
|
|||||
|
2017
Q2 | $47.5M | Sell |
|
|||||
|
2017
Q1 | $56.4M | Sell |
|
|||||
|
2016
Q4 | $56.1M | Buy |
|
|||||
|
2016
Q3 | $43.5M | Buy |
|